144 related articles for article (PubMed ID: 8644624)
1. Reverse use dependence of human ventricular repolarization by chronic oral sotalol in monophasic action potential recordings.
Shimizu W; Kurita T; Suyama K; Aihara N; Kamakura S; Shimomura K
Am J Cardiol; 1996 May; 77(11):1004-8. PubMed ID: 8644624
[TBL] [Abstract][Full Text] [Related]
2. Use-dependent electrophysiologic effects of DL-sotalol and modulation by isoproterenol in the human ventricle.
Naitoh N; Furushima H; Ohira K; Taneda K; Aizawa Y
Jpn Heart J; 1998 Mar; 39(2):153-61. PubMed ID: 9687824
[TBL] [Abstract][Full Text] [Related]
3. Antiarrhythmic effects of selective prolongation of refractoriness. Electrophysiologic actions of sematilide HCl in humans.
Sager PT; Nademanee K; Antimisiaris M; Pacifico A; Pruitt C; Godfrey R; Singh BN
Circulation; 1993 Sep; 88(3):1072-82. PubMed ID: 8353869
[TBL] [Abstract][Full Text] [Related]
4. Practical considerations in the use of sotalol for ventricular tachycardia and ventricular fibrillation.
Campbell RW; Furniss SS
Am J Cardiol; 1993 Aug; 72(4):80A-85A. PubMed ID: 8346732
[TBL] [Abstract][Full Text] [Related]
5. Does sotalol have reverse-use dependence during tachyarrhythmias?
Kovoor P; Byth K; Uther JB; Ross DL
Am J Cardiol; 1996 Jul; 78(2):247-50. PubMed ID: 8712156
[TBL] [Abstract][Full Text] [Related]
6. Drug-induced post-repolarization refractoriness as an antiarrhythmic principle and its underlying mechanism.
Franz MR; Gray RA; Karasik P; Moore HJ; Singh SN
Europace; 2014 Nov; 16 Suppl 4():iv39-iv45. PubMed ID: 25362169
[TBL] [Abstract][Full Text] [Related]
7. Frequency dependent effects of d-sotalol and amiodarone on the action potential duration of the human right ventricle.
Huikuri HV; Yli-Mäyry S
Pacing Clin Electrophysiol; 1992 Nov; 15(11 Pt 2):2103-7. PubMed ID: 1279607
[TBL] [Abstract][Full Text] [Related]
8. Reduction of dispersion of repolarization and prolongation of postrepolarization refractoriness explain the antiarrhythmic effects of quinidine in a model of short QT syndrome.
Milberg P; Tegelkamp R; Osada N; Schimpf R; Wolpert C; Breithardt G; Borggrefe M; Eckardt L
J Cardiovasc Electrophysiol; 2007 Jun; 18(6):658-64. PubMed ID: 17521304
[TBL] [Abstract][Full Text] [Related]
9. Divergent effect of acute ventricular dilatation on the electrophysiologic characteristics of d,l-sotalol and flecainide in the isolated rabbit heart.
Eckardt L; Haverkamp W; Göttker U; Madeja M; Johna R; Borggrefe M; Breithardt G
J Cardiovasc Electrophysiol; 1998 Apr; 9(4):366-83. PubMed ID: 9581953
[TBL] [Abstract][Full Text] [Related]
10. Electrophysiologic mechanisms of antiarrhythmic efficacy of a sotalol and class Ia drug combination: elimination of reverse use dependence.
Lee SD; Newman D; Ham M; Dorian P
J Am Coll Cardiol; 1997 Jan; 29(1):100-5. PubMed ID: 8996301
[TBL] [Abstract][Full Text] [Related]
11. Contribution of delayed ventricular repolarization to the anti-arrhythmic efficacy of sotalol.
Brachmann J; Senges J; Lengfelder W; Jauernig R; Rizos I; Czygan E; Cobbe SM; Kübler W
Eur Heart J; 1985 Nov; 6 Suppl D():171-4. PubMed ID: 3936715
[TBL] [Abstract][Full Text] [Related]
12. d,l-Sotalol at therapeutic concentrations facilitates the occurrence of long-lasting non-stationary reentry during ventricular fibrillation in isolated rabbit hearts.
Hsieh YC; Horng TL; Lin SF; Lin TC; Ting CT; Wu TJ
Circ J; 2009 Jan; 73(1):39-47. PubMed ID: 19008631
[TBL] [Abstract][Full Text] [Related]
13. Randomized crossover comparison of the electrophysiologic and antiarrhythmic efficacy of oral cibenzoline and sotalol for sustained ventricular tachycardia.
Hoffmann E; Mattke S; Haberl R; Steinbeck G
J Cardiovasc Pharmacol; 1993 Jan; 21(1):95-100. PubMed ID: 7678686
[TBL] [Abstract][Full Text] [Related]
14. Prolongation of the human cardiac monophasic action potential by sotalol.
Echt DS; Berte LE; Clusin WT; Samuelsson RG; Harrison DC; Mason JW
Am J Cardiol; 1982 Nov; 50(5):1082-6. PubMed ID: 6127944
[TBL] [Abstract][Full Text] [Related]
15. Rate and time dependent effects of D-sotalol on the monophasic action potential after sudden increase of the heart rate.
Melichercik J; Brachmann J; Schöls W; Hilbel T; Beyer T; Kübler W
Pacing Clin Electrophysiol; 1999 Jan; 22(1 Pt 1):65-72. PubMed ID: 9990602
[TBL] [Abstract][Full Text] [Related]
16. Sympathetic activation, ventricular repolarization and Ikr blockade: implications for the antifibrillatory efficacy of potassium channel blocking agents.
Vanoli E; Priori SG; Nakagawa H; Hirao K; Napolitano C; Diehl L; Lazzara R; Schwartz PJ
J Am Coll Cardiol; 1995 Jun; 25(7):1609-14. PubMed ID: 7759713
[TBL] [Abstract][Full Text] [Related]
17. Predictability of response rates, efficacy, risks, and intolerance with sotalol when used for sustained ventricular arrhythmias.
Reiffel JA
Am Heart J; 1999 Feb; 137(2):372-3. PubMed ID: 10049191
[No Abstract] [Full Text] [Related]
18. Compared effects of sotalol, flecainide and propafenone on ventricular repolarization in patients free of underlying structural heart disease.
Sarubbi B; Ducceschi V; Briglia N; Mayer MS; Santangelo L; Iacono A
Int J Cardiol; 1998 Sep; 66(2):157-64. PubMed ID: 9829329
[TBL] [Abstract][Full Text] [Related]
19. Effects of chronic treatment by amiodarone on transmural heterogeneity of canine ventricular repolarization in vivo: interactions with acute sotalol.
Merot J; Charpentier F; Poirier JM; Coutris G; Weissenburger J
Cardiovasc Res; 1999 Nov; 44(2):303-14. PubMed ID: 10690307
[TBL] [Abstract][Full Text] [Related]
20. Electrophysiologic profile of dronedarone on the ventricular level: beneficial effect on postrepolarization refractoriness in the presence of rapid phase 3 repolarization.
Milberg P; Frommeyer G; Uphaus T; Kaiser D; Osada N; Breithardt G; Eckardt L
J Cardiovasc Pharmacol; 2012 Jan; 59(1):92-100. PubMed ID: 21964157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
